American Thoracic Society

So the CPAP-AHI is actually useful clinically, but it's really a flow-based estimate of residual respiratory events, rather than a PSGR in-lab sleep study, which provides us an apnea-hypopnea index based on arousal and our oxygen desaturation.

In fact, the ATS, the American Thoracic Society, specifically recommends that we call the CPAP-AHI metric as AHI flow so that we can clearly distinguish this from the PSG-derived apnea hypopnea index.

And in fact, in this particular article, they were trying to lean towards that terminology as well, too.

Okay, so what about the technology used in the study as the comparison? If I understand it correctly, it seems the investigators used a single lead ECG, photoplethysmography, and oximetry to generate the comparative data.

You're listening to the ATS Breathe Easy podcast brought to you by the American Thoracic Society.

Welcome back to AKS Now.

I'm your host, Dr. Ugo Ezema.

For the first time ever, the FDA approved a treatment specifically for non-cystic fibrosis bronchiectasis.

And suddenly, a disease that affects roughly half a million Americans has entered a new era.

Our guest today is Dr. Gregory Tino, Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, Chief of the Department of Medicine at Penn Presbyterian Medical Center, Principal Investigator for the COPD Foundation's Bronchiectasis and MTM Research Registry, co-author and the International Consensus Recommendations for Bronchiectasis Diagnosis, and newly elected Treasurer of the American Thoracic Society.

If there's anyone who can walk us through where bronchiectasis stands right now and where it's going, it's Dr. Tino.

Welcome to the show and let's get into it.

Another element to this in terms of who's going to improve is understanding if someone with frailty is actually getting the program that is prescribed.

Really important 2023 American Thoracic Society statement on rehabilitation for people with respiratory disease and frailty.

noted that frail patients were less likely to enroll in pulmonary rehabilitation if they were referred, they were more likely to discontinue it if they began it, and they also held more negative self-perceptions of themselves and around exercise and rehabilitation in general.

However, if they did complete the pulmonary rehabilitation program, they were the ones most likely to derive benefit in terms of improvement in exercise capacity, quality of life, and for many, experience improvement in the severity of their frailty.

The last big talk I did was I was invited.

This is the high point of my entire speaking career, actually, was the American Thoracic Society was holding their international conference.

And there were about 15,000 pulmonologists and chest doctors there.

And they asked me to be the keynote speaker for their plenary session.

So navigating that exact balance is really the core mission of today's Prism Rounds.

In this deep dive, we are going to decode the twenty twenty-six American Thoracic Society Clinical Practice Guideline on Non-Invasive Respiratory Support.

Which was just recently published in the AJRCCM.

Right.

We've not been told whether the growth is cancerous or benign.

The American Thoracic Society says fewer than five percent of lung nodules prove cancerous.

Risk rises with age, size, and factors such as smoking.

At seventy-one, Leo is relatively young for a pope.

It is his first major health scare since he became pope in 2025.

The American Thoracic Society says fewer than 5% of lung nodules turn out to be cancerous.

The U.S. Conference of Catholic Bishops asked the faithful to pray for the pope and his care team.

At the movies, the horror film Other Mommy, starring Jessica Chastain, topped the North American box office in its debut weekend with an estimated $27.5 million, despite poor reviews from both critics and audiences.